What is the main purpose of this 8-K filing by Regeneron Pharmaceuticals?

The main purpose of this 8-K filing is to officially announce and provide access to Regeneron's financial and operating results for the third quarter ended September 30, 2011, through its earnings press release.

Where can I find the detailed financial results for Q3 2011?

The detailed financial results and operational highlights for Q3 2011 are contained within the press release dated October 27, 2011, which is attached as Exhibit 99.1 to this 8-K filing.

Does this 8-K contain specific numbers for revenue or profit?

No, the 8-K filing itself does not contain the specific numerical financial results. It serves as a cover for the press release, which is where investors will find the detailed figures for revenue, profit, and other operational metrics.

What kind of information should I expect in the press release mentioned in the filing?

You should expect to find Regeneron's key financial performance indicators for the quarter (e.g., revenue, net income, earnings per share), updates on their drug development pipeline, significant clinical trial results, and any strategic business developments or outlook provided by the company's management.

REGN 8-K: Earnings & Results

Summary

Regeneron Pharmaceuticals, Inc. (REGN) filed an 8-K on October 27, 2011, to announce its financial and operating results for the third quarter ended September 30, 2011. This filing, furnished under Item 2.02, primarily serves to disseminate the company's earnings press release to the public. Investors should refer to the attached press release (Exhibit 99.1) for detailed information on the quarter's performance, including revenue, profitability, pipeline updates, and any strategic developments. While the 8-K itself does not contain the specific financial figures, it signals that Regeneron has provided its latest performance metrics and operational highlights. Key insights likely contained within the referenced press release would pertain to the progress of its drug development programs, sales performance of existing products (if any), and the company's overall financial health. Investors should consider this filing as the official notification that this information has been made public and is available for review.

Key Highlights

1REGN filed an 8-K on October 27, 2011, reporting Q3 2011 financial and operating results.
2The 8-K filing's primary purpose is to furnish the company's earnings press release (Exhibit 99.1).
3Investors need to consult the attached press release for specific financial and operational details of the quarter ended September 30, 2011.
4This filing marks the public disclosure of REGN's third-quarter performance.
5The press release likely contains information on revenue, earnings, and pipeline development for the period.

REGENERON PHARMACEUTICALS, INC. 8-K Report, Financial Results (Oct 27, 2011)

Summary

Key Highlights

Frequently Asked Questions